Literature DB >> 2763874

Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone.

P Orcel1, J Bielakoff, D Modrowski, L Miravet, M C de Vernejoul.   

Abstract

We investigated a possible "in vivo" effect of cyclosporin A, an immunosuppressive agent, on normal rat bone remodeling. At an oral daily dose of 7 mg/kg for 14 days, the blood level of cyclosporin A was in the usual effective range and no change in renal function or magnesium metabolism was observed. Treated rats had decreased bone resorption: urinary hydroxyproline, plasma acid phosphatase, and the number of osteoclasts in caudal vertebrae were significantly reduced. By contrast, bone formation assessed by dynamic histomorphometry after double tetracycline labeling was increased. No modification of calciotropic hormones (vitamin D metabolites and parathyroid hormone as assessed by urinary cyclic AMP) was observed at the end of the treatment. These results suggest that in vivo cyclosporin A treatment induces bone remodeling modifications related to either a direct or a lymphokine-mediated effect on bone cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2763874     DOI: 10.1002/jbmr.5650040313

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  14 in total

1.  High-turnover osteoporosis is induced by cyclosporin A in rats.

Authors:  Chie Wada; Masatoshi Kataoka; Hiroyuki Seto; Noriko Hayashi; Jun-ichi Kido; Yasuo Shinohara; Toshihiko Nagata
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Cyclosporin A: friend or foe?

Authors:  S Epstein
Journal:  Calcif Tissue Int       Date:  1991-10       Impact factor: 4.333

3.  The effect of cyclosporin A administration on bone metabolism in the rat evaluated by biochemical markers.

Authors:  K Kawana; M Takahashi; K Kushida; H Hoshino; S Sakata; T Inoue
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

4.  Comments on "cyclosporin does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat".

Authors:  S Epstein; W S Jee; Y Ma; C C Liu
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

Review 5.  International consensus recommendations on cyclosporin use in rheumatoid arthritis.

Authors:  P Tugwell
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 6.  Osteoporosis after renal transplantation.

Authors:  Evangelia Dounousi; Konstantinos Leivaditis; Theodoros Eleftheriadis; Vassilios Liakopoulos
Journal:  Int Urol Nephrol       Date:  2014-11-11       Impact factor: 2.370

7.  Continuing loss of vertebral mineral density in renal transplant recipients.

Authors:  B Bagni; P Gilli; A Cavallini; I Bagni; M C Marzola; C Orzincolo; H W Wahner
Journal:  Eur J Nucl Med       Date:  1994-02

8.  Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate.

Authors:  E Meys; F Terreaux-Duvert; T Beaume-Six; G Dureau; P J Meunier
Journal:  Osteoporos Int       Date:  1993-12       Impact factor: 4.507

9.  Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro.

Authors:  L K McCauley; T J Rosol; C C Capen
Journal:  Calcif Tissue Int       Date:  1992-10       Impact factor: 4.333

10.  Effects of cyclosporine A on chick osteoclasts in vitro.

Authors:  M H Chowdhury; V Shen; D W Dempster
Journal:  Calcif Tissue Int       Date:  1991-10       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.